A Post Hoc Analysis of HbA1c Hypoglycemia and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes

摘要

IntroductionAdverse events and complications limit the long-term use of current antidiabetic treatment options for patients with type 2 diabetes mellitus (T2DM), particularly for older adults who are often receiving therapy for other comorbid conditions. The aim of this study was to evaluate the benefits of the dipeptidyl peptidase-4 inhibitor, alogliptin, versus glipizide, a sulfonylurea, in achieving glycemic control without the risk of hypoglycemia, weight gain, or both in older patients with T2DM.